$KZIA leads this week’s BioView Oncology highlights. Shares jumped 45% after early breast cancer trial data showed a >50% drop in circulating tumor cells. More updates coming soon. @KaziaTx

Allurion (NYSE: $ALUR) is expanding into Canada through a new partnership with Minogue Medical, aiming to set a new standard in non-surgical, metabolically healthy weight loss. The collaboration combines Allurion’s gastric balloon and virtual care tech with Minogue’s national.

Shares of MetaVia (Nasdaq: $MTVA) are trading up after the company announced it has dosed the first patient in its highest obesity trial cohort to date. The 48 mg group will help determine the maximum tolerated dose of DA-1726, its dual GLP-1/glucagon receptor agonist. Top-line

(NASDAQ: $PLUG) just locked in a multi-year hydrogen supply deal through 2030—reducing costs and boosting margins as it scales over 275 sites. A big win for the U.S. hydrogen economy, Plug’s bottom line and investors as shares soar 25%. @PlugPowerInc .

RT @ModernRetina: Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program:

$IONQ has been chosen as the primary technology partner for South Korea’s first national quantum center! This milestone strengthens IonQ’s global presence and supports the country’s quantum innovation push. @IonQ_Inc .

(NYSE: $YOU) just launched CLEAR Concierge, a premium add-on for CLEAR+ Members offering high-touch airport services starting at $99. As travel demand surges, this additional revenue stream highlights CLEAR’s strategy to monetize its loyal user base. @Clear

PRISM Mid-Day Movers:.@PlugPowerInc ( $PLUG) jumped 25% after securing a multi-year hydrogen supply deal through 2030, boosting its U.S. hydrogen network and cutting costs across 275+ customer sites. @BitMNR Immersion Technologies ( $BMNR) plunged 45% despite closing a $250M

Yesterday shares of @ZyVersaThera (Nasdaq: $ZVSA) soared on news of support for the FDA-authorized Emergency Compassionate Use of its investigational drug, VAR 200. Check out the PRISM Emerging Biotech Index for more emergers in the space!

$SES AI amps up battery innovation with a new multi-agent AI feature in its Molecular Universe platform! This upgrade enhances materials discovery and accelerates next-gen battery breakthroughs.

$PROK currently leads the PRISM Emerging Biotech Index. Shares are trading up ~50% today and 730% this week following positive Phase 2 trial results. The company will be presenting at H.C. Wainwright Kidney Conference July 14th. @ProKidney .Learn more here:

$RDW expands its global presence with a new AI-focused partnership in Japan! This strategic move strengthens its role in advancing cutting-edge space technologies and international collaboration. @RedwireSpace .

MetaVia (Nasdaq: $MTVA) has hit a key milestone as it begins dosing in the 48 mg cohort of its Phase 1 obesity trial for DA-1726. Early results showed strong weight loss and metabolic benefits—without titration. Top-line data is expected in Q4. #MetaVia.

Shares of $EVOK are soaring today after the company received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its gastroparesis treatment GIMOTI. #StocksInFocus .

$RYTM is hitting all-time highs and leading the Prism MarketView Weight Loss index after releasing positive Phase 2 data for its obesity drug bivamelagon. #StocksInFocus .

$KALA is trying to break above its 200DMA, trading right on it at the moment. #stocks .

$GLXY teams up with Fireblocks to enhance global access to institutional crypto staking! This strategic integration aims to provide secure, scalable solutions for institutional clients entering the staking economy. @GalaxyDigital @FireblocksHQ .

$MGX is currently leading the Prism MarketView Biotech index. Gapping right above its 200DMA at the open, and has continued to rise so far since. #stocks .